Pembrolizumab plus axitinib versus sunitinib monotherapy as firstline treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (vol 21, p1563, 2020)-MedSci.cn

Pembrolizumab plus axitinib versus sunitinib monotherapy as firstline treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (vol 21, p1563, 2020)

Powles, T; Plimack, ER; Soulieres, D

LANCET ONCOLOGY, 2020; 21 (12): E553

科室
- - 订阅+
  - 更多科室
工具
服务